Ginkgo Bioworks Holdings (DNA) Operating Expenses (2020 - 2026)

Ginkgo Bioworks Holdings has reported Operating Expenses for 7 years, with the latest figure at $90.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 23.79% year-over-year to $90.8 million; the trailing twelve-month figure through Mar 2026 stood at $439.0 million (down 36.38% YoY), and the FY2025 full-year result was $485.4 million, down 38.3% from the prior year.
• Operating Expenses for Q1 2026 stood at $90.8 million, down from $104.1 million in the prior quarter.
• The five-year high for Operating Expenses was $843.8 million in Q1 2022, with the low at $90.8 million in Q1 2026.
• Historically, Operating Expenses has averaged $302.8 million across 5 years, with a median of $215.9 million in 2024.
• The largest YoY upside for Operating Expenses was 733.67% in 2022 against a maximum downside of 82.05% in 2022.
• Ginkgo Bioworks Holdings' Operating Expenses stood at $329.1 million in 2022, then slumped by 35.33% to $212.9 million in 2023, then slumped by 30.73% to $147.5 million in 2024, then decreased by 29.37% to $104.1 million in 2025, then dropped by 12.77% to $90.8 million in 2026.
• The last three Operating Expenses figures came in at $90.8 million (Q1 2026), $104.1 million (Q4 2025), and $128.9 million (Q3 2025), per Business Quant data.